Last updated 26 October 2026
Your body already makes a molecule to help calm things down after stress or injury. Most people have never heard of it.
Palmitoylethanolamide, usually shortened to PEA, is a fatty compound your cells make on demand. It acts as a messenger that helps dial down inflammatory signalling, and it is also found in small amounts in food (Rankin and Fowler, 2020; Nestmann, 2017). Some people take it as a supplement, and the research on palmitoylethanolamide is promising in places and thin in others.
That is worth knowing before you buy anything. This guide covers what PEA is, what studies have and have not shown, the different forms, how trials dosed it, and who should speak to a GP first.
Inflammation is meant to switch on, do its job and switch off. With age, that off switch tends to get slower. Researchers call the result inflammaging, a low-level inflammation that lingers and is linked to many of the conditions we associate with getting older (Franceschi et al., 2018). You cannot feel it, although a blood test for inflammation markers such as CRP gives a rough window onto it.
That is why inflammation balance sits at the centre of the five systems that shape how well we age, and why it matters so much for healthspan. Not how long you live, but how many of those years you spend capable and independent.
PEA is interesting because it is part of the body's own braking system. Researchers study it to understand how that brake works, and whether topping it up makes any difference.
Palmitoylethanolamide is a fat-based messenger made by cells throughout the body. It belongs to a family called N-acylethanolamines, and it is built from palmitic acid, a fatty acid found throughout the body and in food (Rankin and Fowler, 2020).
Cells make it when tissue is under stress. It then works mainly through a receptor called PPAR-alpha, which helps switch inflammatory genes up or down, with smaller roles at other receptors such as TRPV1 and GPR55 (Rankin and Fowler, 2020). Because it shares some pathways with the endocannabinoid system, you will sometimes see it described as endocannabinoid-like (Clayton et al., 2021).
PEA is not new. It was identified as a food component in 1957 (Keppel Hesselink et al., 2013). It is found in small amounts in a variety of foods and was first isolated from egg yolk (Nestmann, 2017).
Researchers have looked at several areas, and the results are uneven. A 2025 systematic review gathered 47 randomised trials of PEA. It found the strongest evidence for pain and general wellbeing measures, with good tolerability, while noting the trials covered many different conditions and formulations (Bortoletto et al., 2025).
| Area | What studies looked at | What they found | Strength of evidence |
|---|---|---|---|
| Joint comfort | 111 adults with mild to moderate knee osteoarthritis took 300 mg, 600 mg or a placebo daily for eight weeks (Steels et al., 2019) | Both doses lowered scores for pain and stiffness on a standard knee questionnaire compared with placebo, and the product was well tolerated | One trial |
| Long-term pain | A meta-analysis of 11 double-blind trials in 774 people with chronic pain (Lang-Illievich et al., 2023) | Pain scores were lower with PEA than with comparators, and no major side effects were attributed to it | Promising, small trials of varying quality |
| Sleep | 103 adults with disturbed sleep took 350 mg of a dispersible PEA or a placebo for eight weeks (Rao et al., 2021) | Time to fall asleep and time to feel fully awake were shorter with PEA. Overall sleep quality and quantity did not differ between groups | One trial, mixed results |
| Seasonal allergies | 108 adults took 350 mg of a dispersible PEA or a placebo for two weeks (Briskey et al., 2023) | No overall difference in symptom scores. A difference appeared only in a subgroup with more symptoms | One trial, mixed results |
| Metabolic markers | 58 adults with a BMI of 30 to 40 took PEA or a placebo for 12 weeks (Batacan et al., 2024) | Triglycerides and the immune marker IL-2 fell with PEA. The make-up of the gut microbiome did not change | One trial |
If joints are your main interest, our guide to joint supplements and longevity compares PEA with glucosamine, omega-3, collagen and others.
What the research does not show is that PEA slows ageing or adds years to life. It is studied for how it affects inflammatory signalling and how people feel, not for lifespan. Anyone who tells you otherwise is running ahead of the science.
It is also fair to say the evidence base has gaps. A critical review found the early trials were of variable quality, with problems such as missing data on spread and results reported only at the final time point (Gabrielsson et al., 2016). Newer trials are better designed, but most are still small.
PEA is a fatty molecule, and on its own it does not dissolve well in the watery environment of your gut. Poor oral absorption held back early research, and newer delivery systems were developed to get around it (Clayton et al., 2021). A review of PEA pharmacology notes that much is still unknown about its bioavailability and how it is distributed in the body (Rankin and Fowler, 2020).
| Form | What it is | What research has looked at |
|---|---|---|
| Standard PEA | PEA powder with no special processing | Used in older trials. Absorption is limited (Clayton et al., 2021) |
| Micronised or ultramicronised PEA | PEA ground into much smaller particles | A 2016 review found no head-to-head trials against standard PEA, so superiority was not shown (Gabrielsson et al., 2016) |
| Dispersible PEA | PEA coated so it spreads in water rather than clumping | Used in the sleep and allergy trials above. The 2025 review grouped dispersible forms with micronised ones among the formulations with the strongest evidence (Bortoletto et al., 2025) |
Better absorption does not automatically mean a better outcome. AEVUM wrote this guide, and Daily Vitals uses a dispersible form, so we have tried to be fair to all three. You can read about the form we use, Levagen+ PEA, and the studies behind it on its own page.
Doses in trials vary, and there is no agreed figure. Here is what the research has used. This is what studies did, not a recommendation.
| Source | Dose studied | What it looked at |
|---|---|---|
| Steels et al., 2019 | 300 mg or 600 mg a day for eight weeks | Knee osteoarthritis symptoms |
| Rao et al., 2021 | 350 mg a day for eight weeks | Sleep in adults with disturbed sleep |
| Briskey et al., 2023 | 350 mg a day for two weeks | Seasonal allergy symptoms |
The trials in this guide measured effects over weeks rather than days. More is not better, and higher doses add cost rather than certainty.
PEA has a good safety record so far, with one honest caveat. A review of clinical data found no sign of serious side effects at a rate of one in 200 or more for treatment lasting up to 49 days. Beyond about 60 days, too few people had been studied to rule out rarer effects (Gabrielsson et al., 2016).
A later meta-analysis of chronic pain trials found no major side effects attributed to PEA (Lang-Illievich et al., 2023). Laboratory and animal safety testing has also found no toxic or genetic effects at the doses tested (Nestmann, 2017).
What is missing is good human data in pregnancy and breastfeeding, and long-term data in people taking several medicines. If either applies to you, speak to your GP or pharmacist before taking it.
It depends on who you are, and the honest answer is that nobody knows for certain. Your body makes its own PEA, and food adds a little. For most healthy people there is no proven need to supplement.
If you decide to take one, look for these.
PEA is one part of a bigger picture, and so is Daily Vitals. Daily Vitals contains 375 mg of Levagen+ PEA in each daily serving of three capsules, made with LipiSperse technology from palmitic acid sourced from RSPO certified palm oil, alongside nine other ingredients. PEA has no authorised health claim in Great Britain, so we do not make one.
What we can say is that vitamin C contributes to the normal function of the immune system, and vitamin C and zinc contribute to the protection of cells from oxidative stress (Great Britain NHC Register). They sit alongside strength, movement, sleep and food. You can see every ingredient on our ingredients page. Feel better now. Age better later.
Speak to your GP or pharmacist before starting PEA if you take prescription medicines, are pregnant, trying to conceive or breastfeeding, are due to have surgery or have a medical condition. Do not stop or change a prescribed painkiller or sleep medicine to take a supplement.
Always follow the dose on the label, and remember that a food supplement should not replace a varied diet or medical advice. See your GP if you have ongoing pain, swollen or stiff joints, poor sleep that lasts for weeks, or any symptom that worries you.
PEA is made by your own cells and helps regulate inflammatory signalling. As a supplement it has been studied for joint comfort, long-term pain and sleep, with mixed and mostly small trials (Bortoletto et al., 2025).
No. PEA here stands for palmitoylethanolamide, a fatty compound. Pea protein comes from peas and has nothing to do with it.
No. It shares some pathways with the body's endocannabinoid system and is sometimes called endocannabinoid-like, but it works mainly through a different receptor, PPAR-alpha (Rankin and Fowler, 2020). It does not come from cannabis.
PEA is found in small amounts in a variety of foods and was first identified in egg yolk (Nestmann, 2017). The amounts in a normal diet are much smaller than the doses used in trials.
The trials in this guide lasted from two to 12 weeks, and the joint and sleep trials measured effects at eight weeks (Steels et al., 2019; Rao et al., 2021). That does not mean you will notice anything.
It has been well tolerated in trials of up to several weeks, with no serious side effects reported (Gabrielsson et al., 2016; Lang-Illievich et al., 2023). There is less data on use beyond about two months.
Keep reading
Joint supplements and longevity, which have evidence
Inflammation markers and what CRP tests show
CoQ10 benefits and longevity
References
Batacan, R., Briskey, D., Bajagai, Y.S., Smith, C., Stanley, D. and Rao, A. (2024). Effect of palmitoylethanolamide compared to a placebo on the gut microbiome and biochemistry in an overweight adult population, a randomised, placebo controlled, double-blind study. Biomedicines, 12(7), 1620. doi.org
Bortoletto, R. et al. (2025). Palmitoylethanolamide supplementation for human health, a state-of-the-art systematic review of randomized controlled trials in patient populations. Brain, Behavior, and Immunity Health, 43, 100927. doi.org
Briskey, D., Ebelt, P. and Rao, A. (2023). The effect of Levagen+ (palmitoylethanolamide) supplementation on symptoms of allergic rhinitis, a double-blind placebo-controlled trial. Nutrients, 15(23), 4940. doi.org
Clayton, P., Hill, M., Bogoda, N., Subah, S. and Venkatesh, R. (2021). Palmitoylethanolamide, a natural compound for health management. International Journal of Molecular Sciences, 22(10), 5305. doi.org
Franceschi, C. et al. (2018). Inflammaging, a new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology, 14, 576–590. doi.org
Gabrielsson, L., Mattsson, S. and Fowler, C.J. (2016). Palmitoylethanolamide for the treatment of pain, pharmacokinetics, safety and efficacy. British Journal of Clinical Pharmacology, 82(4), 932–942. doi.org
Great Britain Nutrition and Health Claims (NHC) Register. Department of Health and Social Care. gov.uk
Keppel Hesselink, J.M., de Boer, T. and Witkamp, R.F. (2013). Palmitoylethanolamide, a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. International Journal of Inflammation, 2013, 151028. doi.org
Lang-Illievich, K. et al. (2023). Palmitoylethanolamide in the treatment of chronic pain, a systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients, 15(6), 1350. doi.org
Nestmann, E.R. (2017). Safety of micronized palmitoylethanolamide (microPEA), lack of toxicity and genotoxic potential. Food Science and Nutrition, 5(2), 292–309. doi.org
Rankin, L. and Fowler, C.J. (2020). The basal pharmacology of palmitoylethanolamide. International Journal of Molecular Sciences, 21(21), 7942. doi.org
Rao, A., Ebelt, P., Mallard, A. and Briskey, D. (2021). Palmitoylethanolamide for sleep disturbance, a double-blind, randomised, placebo-controlled interventional study. Sleep Science and Practice, 5, 12. doi.org
Steels, E., Venkatesh, R., Steels, E., Vitetta, G. and Vitetta, L. (2019). A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology, 27(3), 475–485. doi.org
Balance inflammation, support cellular resilience and build long-lasting vitality.
Welcome Gift
